News >

Immunology Biomarkers Taking Shape in Breast Cancer

Anita T. Shaffer @Shaffer1
Published: Monday, Feb 15, 2016

Elias Obeid, MD, MPH

Elias Obeid, MD, MPH

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes, according to a recent review of research findings from the 2015 San Antonio Breast Cancer Symposium (SABCS).

Abstracts exploring tumor-infiltrating lymphocytes (TILs) and CD8-positive T cells as prognostic markers were among the immunology highlights presented at SABCS, said Elias Obeid, MD, MPH, an assistant professor in the departments of Clinical Genetics and Medical Oncology at Fox Chase Cancer Center.

Obeid spoke during an annual SABCS review that Fox Chase organized in January for oncology specialists and healthcare professionals throughout the Philadelphia region. Lori J. Goldstein, MD, director of the Naomi and Phil Lippincott Breast Evaluation Center and deputy associate director of Clinical Research at Fox Chase, served as program chair for the event, which also featured researchers from the Hospital of the University of Pennsylvania.

The focus on immunological biomarkers in breast cancer has been growing in recent years as evidence builds about the prognostic and potentially predictive value of TILs in triple-negative breast cancer (TNBC) and HER2-overexpressing breast cancer. At the same time, monoclonal antibodies that target the PD-1/PD-L1 immune checkpoints are being investigated in breast cancer following their success in melanoma and non–small cell lung cancer, intensifying the importance of identifying immune system biomarkers.

Last year, the International TILs Working Group of breast cancer researchers called for a standardized methodology for evaluating TILs that could be employed in research and in clinical trials.1 The group also noted that the presence of specific subsets of immune cells, notably cytotoxic CD8-positive T cells, have been correlated with clinical responses to therapy in breast cancer.1

For TILs, the Working Group said that values should be reported for the stromal compartment; that is, as the percentage of stromal TILs in the area of stromal issue. They did not make a recommendation on a clinically relevant TIL threshold.

In his presentation, Obeid recapped key points and findings from 3 SABCS abstracts concerning these immunology biomarkers.

Tumor-Infiltrating Lymphocytes

In one study, Loi et al2 analyzed pooled data from 991 patients with early-stage TNBC treated with adjuvant chemotherapy during 6 randomized clinical trials. Sixty-two percent of the patients had been treated with anthracycline plus taxane chemotherapy, while 38% were treated with an anthracycline-based regimen alone.

The researchers were seeking to “achieve a robust understanding” of the prognostic value of TILs in this disease setting; secondary objectives included developing a model to determine the value of TILs as an added variable to standard clinicopathological factors.

The investigators measured intratumoral TILs, defined as those lymphocytes with direct contact to tumor cells, and stromal TILs, which are between the tumor cells but within the tumor stroma. Overall, the average value of stromal TILs was 20%, and 90% of patients had at least 1% stromal TILs in the samples tested, investigators indicated.

The study showed that the presence of stromal TILs was associated with a 16% reduction in both invasive disease-free survival (DFS) events and in the risk of death (HR, 0.84). On multivariate analysis, researchers found that stromal TILs were significantly associated with invasive and distant DFS and with overall survival.

However, intratumoral TILs did not significantly correlate with outcomes, noted Obeid. Moreover, patient age and nodal status were not significantly associated with TILs but “larger tumor size had lower infiltration with lymphocytes,” Obeid said.

In conclusion, Obeid said, patients with node-negative TNBC and stromal TILs ≥20% have excellent 5-year distant DFS outcomes, making it possible to develop a model to predict risk of distant recurrence incorporating TILs.

“For every 10% increase in stromal infiltration in the tumor, there was about a 12% relative risk reduction adjusted for different variables,” Obeid noted. “Clinical pathologic factors in addition to stromal infiltrating tumor lymphocytes seem to be enough in this model.”

In their abstract, researchers concluded that stromal TILs should be “strongly considered” as a stratification factor in future clinical trials for patients with TNBC. “Given the important prognostic role of preexisting immunity, patients with TNBC are rational candidates for immunotherapy clinical trials,” they added.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication